End-of-day quote
Shenzhen S.E.
06:00:00 2024-05-08 pm EDT
|
5-day change
|
1st Jan Change
|
26.76
CNY
|
+0.83%
|
|
+2.45%
|
-16.61%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
40,942
|
26,956
|
22,339
|
-
|
-
|
Enterprise Value (EV)
1 |
40,942
|
26,956
|
22,339
|
22,339
|
22,339
|
P/E ratio
|
73.1
x
|
40.6
x
|
28.5
x
|
20.5
x
|
21.2
x
|
Yield
|
0.38%
|
0.34%
|
0.41%
|
-
|
-
|
Capitalization / Revenue
|
12.7
x
|
6.72
x
|
4.81
x
|
3.53
x
|
3.65
x
|
EV / Revenue
|
12.7
x
|
6.72
x
|
4.81
x
|
3.53
x
|
3.65
x
|
EV / EBITDA
|
44
x
|
22.8
x
|
16.1
x
|
12.9
x
|
12.7
x
|
EV / FCF
|
76.1
x
|
52.4
x
|
24.4
x
|
20
x
|
13.6
x
|
FCF Yield
|
1.31%
|
1.91%
|
4.1%
|
4.99%
|
7.38%
|
Price to Book
|
8.01
x
|
4.77
x
|
3.48
x
|
3.02
x
|
2.72
x
|
Nbr of stocks (in thousands)
|
840,000
|
840,000
|
834,775
|
-
|
-
|
Reference price
2 |
48.74
|
32.09
|
26.76
|
26.76
|
26.76
|
Announcement Date
|
4/23/23
|
4/25/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
3,233
|
4,013
|
4,645
|
6,325
|
6,124
|
EBITDA
1 |
-
|
931.1
|
1,181
|
1,386
|
1,732
|
1,763
|
EBIT
1 |
-
|
727.4
|
973.4
|
1,162
|
1,530
|
1,600
|
Operating Margin
|
-
|
22.5%
|
24.26%
|
25.02%
|
24.19%
|
26.13%
|
Earnings before Tax (EBT)
1 |
-
|
653.6
|
854.3
|
998.8
|
1,406
|
1,348
|
Net income
1 |
454.9
|
511.8
|
665.9
|
788.4
|
1,099
|
1,061
|
Net margin
|
-
|
15.83%
|
16.59%
|
16.97%
|
17.37%
|
17.33%
|
EPS
2 |
0.6067
|
0.6667
|
0.7900
|
0.9400
|
1.308
|
1.260
|
Free Cash Flow
1 |
-
|
538.2
|
514.5
|
914.9
|
1,115
|
1,648
|
FCF margin
|
-
|
16.65%
|
12.82%
|
19.7%
|
17.63%
|
26.9%
|
FCF Conversion (EBITDA)
|
-
|
57.81%
|
43.58%
|
65.99%
|
64.39%
|
93.46%
|
FCF Conversion (Net income)
|
-
|
105.17%
|
77.27%
|
116.05%
|
101.51%
|
155.29%
|
Dividend per Share
2 |
-
|
0.1867
|
0.1100
|
0.1100
|
-
|
-
|
Announcement Date
|
10/13/22
|
4/23/23
|
4/25/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q1
|
---|
Net sales
|
-
|
EBITDA
|
-
|
EBIT
|
-
|
Operating Margin
|
-
|
Earnings before Tax (EBT)
|
-
|
Net income
|
-
|
Net margin
|
-
|
EPS
1 |
0.1800
|
Dividend per Share
|
-
|
Announcement Date
|
4/23/23
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
538
|
515
|
915
|
1,115
|
1,648
|
ROE (net income / shareholders' equity)
|
-
|
20.1%
|
12.4%
|
13%
|
14.9%
|
13.7%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
9.44%
|
10.8%
|
11.5%
|
-
|
Assets
1 |
-
|
-
|
7,057
|
7,317
|
9,526
|
-
|
Book Value Per Share
2 |
-
|
6.090
|
6.730
|
7.690
|
8.870
|
9.830
|
Cash Flow per Share
2 |
-
|
0.9200
|
1.140
|
1.300
|
1.790
|
1.600
|
Capex
1 |
-
|
232
|
447
|
359
|
331
|
239
|
Capex / Sales
|
-
|
7.17%
|
11.13%
|
7.73%
|
5.23%
|
3.91%
|
Announcement Date
|
10/13/22
|
4/23/23
|
4/25/24
|
-
|
-
|
-
|
Last Close Price
26.76
CNY Average target price
50.02
CNY Spread / Average Target +86.92% Consensus |
1st Jan change
|
Capi.
|
---|
| -16.61% | 3.09B | | -12.96% | 2.95B | | -58.09% | 2.16B | | +6.53% | 234M | | -46.54% | 174M | | -32.40% | 115M |
Doctor's Office
|